ReviewDrugs2003
Early intervention in multiple sclerosis : better outcomes for patients and society?
Review in Drugs, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Improving Patient-Centered Care by Assessing Patient Preferences for Multiple Sclerosis Disease-Modifying Agents: A Stated-Choice Experiment.The Permanente journal · 2017Trial
- Multiple sclerosis risk stratification and healthcare cost prediction using machine learning.Communications medicine · 2025Article
- The management of multiple sclerosis by reference centers in south of Italy: a 2011 survey on health demands and needs in Campania region.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2016Article
- Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.Autoimmune diseases · 2012Article
- When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?Multiple sclerosis international · 2011Article
- Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis.PloS one · 2010Article
- Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study.Clinical drug investigation · 2010Article
- Interferon-beta-1b: in newly emerging multiple sclerosis.CNS drugs · 2008Review
- Analysis of NAMCS data for multiple sclerosis, 1998-2004.BMC medicine · 2007Article
- [Quality of life in multiple sclerosis. Measures, relevance, problems, and perspectives].Der Nervenarzt · 2005Review
- Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis.CNS drugs · 2005Review
- Improving MS patient care.Journal of neurology · 2004Review
- Mitoxantrone: a review of its use in multiple sclerosis.CNS drugs · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is thought to be a chronic inflammatory disorder of the CNS. The past decade has seen the introduction of the new immunomodulatory drugs, interferon (IFN)-beta and glatiramer acetate, that have considerably improved the therapeutic options for this often disabling disease. The efficacy of these treatments in terms of reducing relapse rate and slowing progression has been proven in several large, multicentre, randomised, controlled trials. Similarly, early IFNbeta treatment of patients with clinically isolated syndromes suggestive of MS has been shown to lengthen time to conversion into definite MS. Cost-effectiveness has been questioned with the increasing use of these innovative and, therefore, costly therapies; however, modern studies with appropriate economic modelling suggest that treatment with IFNbeta may indeed be cost-effective. Since increasing disability is associated with increasing costs, stabilisation of the disease at low functional grades of disability should aim at not only improving quality of life for the individual patient, but provide for prospective cost-benefit analysis focussing on the socioeconomic aspects of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.